Singlera Genomics raises $150 million in Series B financing to promote the development and commercialization of early cancer screening products
News provided by
Share this article
Share this article
SAN DIEGO and SHANGHAI, Dec. 15, 2020 /PRNewswire/ Singlera Genomics Inc. today announced that it raised $150 million in Series B financing. This round of financing was led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. The new group of investors also include Huamei International, Linden Asset Group, Wuxi Capital, FutureX Skyline Capital, Shanghai Free Trade Zone Fund, and initial investors from the Series A round such as Greenpine Capital, Prosperico Ventures, and Proxima Ventures joined with follow-on investment. Singlera will utilize this round of financing mainly to expand the company s early cancer screening product research and development pipeline and focus on promoting product registration and commercialization, as well
December 15, 2020
SAN DIEGO and SHANGHAI, Dec. 15, 2020 /PRNewswire/ Singlera Genomics Inc. today announced that it raised $150 million in Series B financing. This round of financing was led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. The new group of investors also include Huamei International, Linden Asset Group, Wuxi Capital, FutureX Skyline Capital, Shanghai Free Trade Zone Fund, and initial investors from the Series A round such as Greenpine Capital, Prosperico Ventures, and Proxima Ventures joined with follow-on investment. Singlera will utilize this round of financing mainly to expand the company s early cancer screening product research and development pipeline and focus on promoting product registration and commercialization, as well as expanding prospective studies into pan-cancer early screening.